Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Yamagata, not included in 2017/18 trivalent vaccines) co-circulated in Europe. Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, -42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates.
Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies / Marc, Rondy; Esther, Kissling; Hanne-Dorthe, Emborg; Alin, Gherasim; Richard, Pebody; Ramona, Trebbien; Francisco, Pozo; Amparo, Larrauri; Jim, Mcmenamin; Marta, Valenciano; D'Agaro, Pierlanfranco. - In: EUROSURVEILLANCE. - ISSN 1560-7917. - ELETTRONICO. - 23:9(2018), pp. 18-00086."-"-18-00086."-". [10.2807/1560-7917.ES.2018.23.9.18-00086]
Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies
Pierlanfranco D'AgaroMembro del Collaboration Group
2018-01-01
Abstract
Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Yamagata, not included in 2017/18 trivalent vaccines) co-circulated in Europe. Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, -42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates.| File | Dimensione | Formato | |
|---|---|---|---|
|
eurosurv-23-9-1.pdf
accesso aperto
Tipologia:
Documento in Versione Editoriale
Licenza:
Creative commons
Dimensione
532.52 kB
Formato
Adobe PDF
|
532.52 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
